Autologous stem cell therapy - DaVinci Biosciences

Drug Profile

Autologous stem cell therapy - DaVinci Biosciences

Alternative Names: DVM™

Latest Information Update: 23 Oct 2009

Price : $50

At a glance

  • Originator DaVinci Biosciences
  • Class Cardiovascular therapies; Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Spinal cord injuries

Most Recent Events

  • 21 Oct 2009 Interim efficacy and adverse events data from a clinical trial in Spinal cord injuries presented at the 39th Annual Meeting of the Society for Neuroscience (SfN- 2009),
  • 12 Mar 2009 Clinical trials in Spinal cord injuries in Ecuador (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top